Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

<i>AKT1</i> Amplification Regulates Cisplatin Resistance in Human Lung Cancer Cells through the Mammalian Target of Rapamycin/p70S6K1 Pathway

1 Jul 2007

Abstract excerpt

Cisplatin [cis-diaminodichloroplatinum (II) (CDDP)] is one of the most widely used and effective therapeutic agents for many kinds of cancers. However, its efficiency is limited due to development of drug resistance. In this study, we showed that CDDP resistance was associated with AKT1 overexpression and gene amplification in human lung cancer cells that acquired the drug resistance. We showed that AKT1 forced...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Chemotherapy-induced organ toxicity mitigation
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 17616691
DOI: 10.1158/0008-5472.can-06-4261

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

<i>AKT1</i> Amplification Regulates Cisplatin Resistance in Human Lung Cancer Cells through the Mammalian Target of Rapamycin/p70S6K1 PathwayPMID 17616691Read ↗

PI3K/AKT signaling pathway as a critical regulator of Cisplatin response in tumor cellsSemantic proximity Read ↗

Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review).Semantic proximity Read ↗

PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities.Semantic proximity Read ↗

The mechanism of ABL1 upregulating the expression of PD-L1 and the therapeutic effect of PD-L1 and STAT3 inhibitors in lung adenocarcinoma.Semantic proximity Read ↗

Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer.Semantic proximity Read ↗

New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer.Semantic proximity Read ↗

Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations.Semantic proximity Read ↗

Molecular alterations in apoptotic pathways after PKB/Akt-mediated chemoresistance in NCI H460 cellsSemantic proximity Read ↗

Mcl-1 Interacts with Akt to Promote Lung Cancer ProgressionSemantic proximity Read ↗

High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886).Semantic proximity Read ↗

HtrA1 Downregulation Induces Cisplatin Resistance in Lung Adenocarcinoma by Promoting Cancer Stem Cell‐Like PropertiesSemantic proximity Read ↗

Molecularly targeting the PI3K-Akt-mTOR pathway can sensitize cancer cells to radiotherapy and chemotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.